Detalhe da pesquisa
1.
BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients.
Breast Cancer Res Treat
; 174(3): 775-783, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30635808
2.
[Screening of ovarian cancer : not for tomorrow]. / Dépistage du cancer de l'ovaire : ce n'est pas pour demain.
Rev Med Suisse
; 13(563): 1039-1041, 2017 May 17.
Artigo
em Francês
| MEDLINE | ID: mdl-28636295
3.
Chemotherapy-related agranulocytosis as a predictive factor for germline BRCA1 pathogenic variants in breast cancer patients: a retrospective cohort study.
Swiss Med Wkly
; 153: 40055, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37011610
4.
Hematologic toxicities of chemotherapy in breast and ovarian cancer patients carrying BRCA1/BRCA2 germline pathogenic variants. A single center experience and review of the literature.
Fam Cancer
; 22(3): 283-289, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37119509
5.
Impact of Radiochemotherapy on Immune Cell Subtypes in High-Grade Glioma Patients.
Front Oncol
; 10: 89, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32117743
6.
Publisher Correction: Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
Sci Rep
; 10(1): 19248, 2020 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33139817
7.
Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes.
Sci Rep
; 10(1): 7073, 2020 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32341426